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ABSTRACT  
BACKGROUND: Patients treated for soft tissue sarcoma (STS) require long-term follow-up to 
detect recurrent or metastatic disease, yet marked differences exist in clinical approaches to the 
length of follow-up, frequency of consultations and investigations undertaken at follow-up visits. 
There has been no published work assessing patient expectations or the acceptability of post-
treatment follow-up strategies. This study aimed to assess the patient acceptability of different 
follow-up strategies following curative surgery for soft tissue sarcoma and to investigate the 
hypothetical levels of recurrence risk at which different follow-up regimes were acceptable.  
 
METHODS: Patients were recruited from the Royal Orthopaedic Hospital in Birmingham. The 
study used a cross-sectional survey incorporating a best-worst scaling discrete choice 
experiment to assess patient preferences regarding different aspects of follow-up. 
 
RESULTS: 132 patients participated (47% response). The nature of investigations undertaken 
during follow-up was the most important aspect of post-surgical care. Patients typically preferred 
appointments routinely consisting of clinical examination and chest x-ray, and for follow-up to 
remain in secondary care rather than general practice.  
 
CONCLUSION: Clear protocols for STS patient follow-up can improve consistency and equity of 
care. In determining the optimum follow-up plan for STS patients from the patient perspective, 
this study provides valuable information that should be considered alongside the clinical 
effectiveness of follow-up strategies to maximise patient outcomes and use NHS resources 
appropriately. 
 
 
Keywords: soft tissue sarcoma, follow-up, secondary care, discrete choice experiment, best-
worst scaling
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INTRODUCTION 
In England, approximately 2,300 patients are diagnosed with soft tissue sarcoma (STS) each 
year [1]. STS can occur in any anatomical location [2], and surgical excision with or without 
adjuvant radiotherapy is the usual treatment for localised disease [3]. However, there is a 
significant risk of local recurrence and metastasis following primary treatment. Ten-year local 
recurrence rates are between 10 and 20%, and ten-year survival is 50 to 60% [4,5] Within this, 
there can be significant variability by tumour type, size and location [6,7]. Prognostic factors for 
tumour relapse are complex; the risk of metastasis is associated with tumour grade, size and 
depth, while local recurrence risk is associated with grade and excision margin [5].  
 
Given the risk of recurrence or metastasis following primary treatment, STS patients require 
long-term follow-up, which may continue for up to ten years. However, there remains 
controversy as to the optimum patient follow-up regime, and follow-up may produce either 
reassurance or anxiety for patients [8,9], particularly as 40% or more of patients will never 
develop recurrent disease [1,10].   
 
Routine follow-up includes clinical examination and regular chest x-rays, but the value of more 
sophisticated follow-up investigations remains uncertain [1]. US studies demonstrate significant 
heterogeneity in clinical practice [11,12]. The American National Comprehensive Cancer 
Network and American College of Radiology have produced consensus-based guidelines for 
sarcoma follow-up [13], stratified by grade and tumour site. A survey of UK practice showed 
differences in the length of follow-up, frequency of consultations and the investigations 
undertaken at follow-up visits [14]. The National Comprehensive Cancer Network in the UK has 
issued post-treatment guidelines for the clinical management of STS but these are consensus 
rather than evidence-based [15].  Finally, the European Society for Medical Oncology (ESMO) 
has issued its own follow-up guidelines, recommending tailored patient follow-up regimes based 
on risk assessments of tumour grade, size and site [16]. In addition to clinical uncertainty about 
STS follow-up, there is no published work assessing the acceptability of different potential post-
treatment regimes from the patient perspective.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
 
This study aimed to assess the patient acceptability of different follow-up strategies following 
curative STS surgery and to investigate the hypothetical levels of recurrence risk at which 
different follow-up regimes were acceptable.   
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
PATIENTS AND METHODS 
This study used a cross-sectional survey incorporating a best-worst scaling (BWS) discrete 
choice experiment (DCE) to elicit information regarding patient preferences for different aspects 
of the STS follow-up regime. Participants were also asked to choose between low, moderate 
and intensive follow-up schedules at a range of hypothetical recurrence risks from 0% to 100%. 
 
Patient recruitment and data collection 
The Royal Orthopaedic Hospital (ROH) maintains a database of patients treated for soft tissue 
sarcoma, which was searched by a research nurse to identify eligible participants aged 18 and 
over, with a diagnosis of any soft tissue tumour (excluding retroperitoneal or periabdominal 
sarcomas as these patients are not followed up at ROH) who had undergone curative 
treatment. Patients were not eligible for the study if they were aged under 18 at the time of 
primary treatment, were diagnosed fewer than 6 months or more than 10 years previously, or 
had a serious or unstable medical or psychological condition that would compromise study 
participation.  
 
All eligible patients were posted a study information pack seven days before their next follow-up 
clinic visit. On arrival at the clinic, the research nurse took informed consent from those who 
wished to participate in the study, and administered the survey and DCE. Sociodemographic 
information (age, gender, employment status, education level, distance between patients’ home 
and ROH) was collected, and anonymised clinical information was extracted from the hospital 
database for each participant. This included data relating to primary treatment (age, date of 
diagnosis and treatment, STS histology, tumour size, grade, site), and any information relating 
to disease recurrence.  
 
Discrete choice experiment and best-worst scaling 
Discrete choice experiments (DCE) elicit preferences for goods or services based on individual 
intentions in hypothetical situations [17]. The DCE method has several variants; this study used 
the best-worst scaling method [18,19], which identifies patient preferences for healthcare 
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service provision by examining trade-offs that individuals are prepared to make between 
different aspects of healthcare. BWS involves identification of key characteristics (attributes), 
each of which has two or more levels, in order to develop a series of scenarios incorporating 
various combinations of attribute levels to describe different aspects of healthcare service 
provision [20]. Attributes were derived from published literature [11,12,14], and clinical 
guidelines [15, 21-23].  
 
Four attributes were chosen: length of follow-up, frequency of follow-up visits, clinical 
investigations and choice of healthcare provider. These were perceived to best combine the 
important characteristics of follow-up appointments in the simplest manner. Each attribute was 
assigned three levels, derived from the literature and clinical relevance. As the inclusion of all 
possible combinations of attributes and levels would result in 81 (34) scenarios, a subset of nine 
orthogonal scenarios (fractional factorial design) was obtained via a statistical design website 
(http://www.research.att.com/~njas/oadir/) [24]. For each scenario, participants were asked to 
choose the aspect that they perceived as the best and worst option (Figure 1). 
 
Acceptability of follow-up at different risks of recurrence 
Participants were also asked to choose their preferred follow-up schedule (low, moderate and 
intensive) at a range of hypothetical recurrence risks ranging from 0% to 100%. Low-level 
follow-up comprised one follow-up visit per year in general practice, incorporating only a clinical 
examination. Moderate follow-up comprised two visits annually, conducted by a specialist 
hospital nurse, including clinical examination and chest x-ray. Intensive follow-up consisted of 
quarterly visits to a specialist hospital doctor, incorporating a clinical examination and 
MRI/CT/ultrasound scan.  
 
Data analysis 
BWS analysis focused on the number of times a participant chose a particular attribute/level as 
best or worst. Each best-worst combination was analysed as paired data, plotted as one data 
point at the individual level, and assessed using conditional multinomial logistic regression. The 
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regression co-efficients indicate the additional utility value for each attribute-level in comparison 
to the baseline provided by the lowest rated attribute-level. Utility values can be interpreted in a 
cardinal way e.g. if the difference in level values for one attribute is twice that of another 
attribute, this corresponds to twice the value of improving the level on the former attribute. The 
method also allows an assessment of the scenario that contains the highest number of 
desirable components, has the highest utility value, and is acceptable to most participants. 
Patient preferences for low, moderate or intensive follow-up schedules were analysed 
descriptively and the results presented graphically. Data were analysed using Stata version 12 
(StataCorp, 2011). 
 
Justification of sample size  
The sample size was based on pragmatic rather than statistical criteria and was maximised 
within the resources available. It was anticipated that 300 patients would be eligible to 
participate during the data collection period (May to December 2012). Achieving a 60% 
response rate would thus give a sample size of 180 patients. 
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RESULTS 
Response rates 
286 patients were eligible to participate over the data collection period. 133 patients consented 
to participate, representing a 47% response rate. One participant withdrew after consenting, 
thus data were collected for 132 patients in total. 
 
Participant clinical and sociodemographic characteristics 
73 participants were male (55%) and 59 were female (45%), (Table 1). Median age at time of 
survey completion was 63 years (inter-quartile range (IQR): 47 to 71), with median age at 
primary diagnosis 57 years (IQR 43 to 67). Median travel time between a participant’s home 
and ROH was 60 minutes (IQR 45 to 90). The most common tumour type was a high grade 
primary tumour (n=62; 47%), and most tumours occurred in the lower extremity (n=82; 62%). 
Mean tumour size (diameter) at diagnosis was 9.2cm. 
 
Participant views about follow-up 
Participants were asked for their general views about STS follow-up and its perceived 
importance. All participants felt that attending follow-up visits was important, and the vast 
majority (n=130; 99%) understood why follow-up visits were necessary. Most respondents felt it 
important to be included in decision-making about their follow-up regime (n=114; 86%). The 
most important broad aspect of follow-up visits for most participants was the nature of clinical 
investigations undertaken (n=96; 73%). The type of healthcare provider conducting follow-up 
was deemed the least important factor (n=7; 5%).   
 
Discrete choice experiment best-worst scaling 
Table 2 shows the frequency with which specific attributes and levels were selected as best or 
worst choices, and outlines the overall rank for each level derived from the number of times it 
was chosen as the best or worst aspect of a scenario.  The three highest ranked levels were all 
aspects of the attribute relating to preferred clinical investigations, with clinical examination and 
x-ray rated highest. The lowest ranked level was follow-up undertaken by a general practitioner, 
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which was ranked as the best aspect of a scenario 19 times, and ranked worst on 251 
occasions. Participants ranked follow-up visits undertaken by a specialist hospital doctor fourth 
out of the 12 levels assessed overall. Within the frequency of follow-up attribute, 6-monthly 
clinic visits were seen as most acceptable, and most participants’ preferred length of follow-up 
was five years after primary treatment. 
 
Table 3 shows the conditional logistic regression model of best-worst pairs. As follow-up carried 
out by general practitioners ranked as the least preferred of all options, this level was assigned 
a value of zero and the utility for all other coefficients estimated relative to this baseline. Model 
coefficients indicated that clinical examination with x-ray was the most highly valued attribute 
level, followed by clinical examination plus intensive investigations and follow-up visits 
conducted by a specialist hospital doctor. In terms of individual attributes, the one that made the 
most difference to patients was the healthcare provider. The additional value of seeing a 
hospital specialist as compared to a GP (1.89) was equal to almost three times the additional 
value of having an x-ray at clinical examination compared to clinical examination without x-ray 
(0.68 i.e. 2.503 minus 1.823). Coefficients with the lowest utility (thus representing the least 
valued attribute levels) were those relating to lifelong follow-up duration and the most frequent 
follow-up option of a quarterly clinic visit. Taking the highest valued level within each attribute 
together, the preferred scenario across the patient cohort would be 6-monthly follow-up for five 
years, in which a hospital doctor carries out a clinical examination and x-ray. 
 
Acceptability of follow-up schedule by hypothetical risk of disease recurrence 
Figure 2 shows the number of survey respondents who chose each of the three types of follow-
up schedule at different hypothetical levels of disease recurrence risk. 17 participants (12.9%) 
would choose an intensive follow-up schedule even if they had no risk of disease recurrence, 
and 4 participants (3.0%) would opt for a moderate level of follow-up even with a 100% risk of 
recurrence. As might be expected, as the hypothetical risk of recurrence increased, the number 
of patients who would prefer a more intensive follow-up regime also increased. Once the risk of 
recurrence became greater than 5%, the intensive follow-up schedule increasingly became the 
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preferred choice, whilst between 1% and 5%, the moderate follow-up schedule was dominant, 
and below 1%, the low level schedule was preferred. 
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DISCUSSION 
The main aim of patient follow-up after primary treatment for soft tissue sarcoma is to detect 
recurrent disease at a time when further treatment can positively influence patient outcomes. 
STS recurrence rates are high, and regular follow-up can reassure patients about their risk of 
relapse or developing metastasis as well as providing important opportunities for patients to 
raise issues regarding physical or psychological consequences of primary treatment. Present 
guidelines recommend that active follow-up should continue for at least five years, thus at any 
one time, approximately 15,000 patients in the UK will be involved at some stage in the follow-
up process.  
 
This study is the largest investigation of follow-up issues in patients with STS to date, and the 
DCE best-worst scaling method allowed patients to express preferences for specific aspects of 
the STS follow-up strategy, thus identifying those with the greatest utility values. Patients 
perceived the nature of clinical investigations undertaken at follow-up appointments to be the 
most important aspect of overall post-surgical care and most expressed a preference for follow-
up appointments routinely consisting of clinical examination and chest x-ray. As well as being 
acceptable to most patients, this form of follow-up investigation is clinically sound given that 
relapses occur most often in the lungs.  
 
Although studies comparing the acceptability of GP vs. hospital clinic follow-up have been 
undertaken for other tumour types (such as breast cancer) and shown that GP follow-up was 
perceived favourably by patients [25], participants in this study expressed strong preferences for 
follow-up to remain in secondary care, as the greatest gain in utility between levels evident 
within a single attribute was the difference between GP follow-up and follow-up undertaken by a 
specialist hospital doctor. This may be because patients with STS often experience diagnostic 
delays within general practice [26] and as a consequence, may have less confidence in their GP 
facilitating long-term follow-up after completion of treatment. Furthermore, the rarity of soft 
tissue sarcoma and generally poor prognosis after treatment may be a factor in the observed 
strong patient preference for specialist follow-up and ongoing monitoring.   
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Follow-up for soft tissue sarcoma patients is necessary, yet time-consuming and resource-
intensive and the lack of consensus about the optimal follow-up strategy has led to significant 
variation in clinical practice within and between countries. Follow-up is a question of balancing 
multiple objectives, including maximising patient survival, quality of life, psychological outcomes 
and physical function [27]. There is clearly some scope for tailored follow-up regimes developed 
on a case-by-case basis. This study has shown that whilst patient follow-up preferences were 
generally homogeneous, these preferences changed once the issue of recurrence risk was 
considered. The thresholds at which patient preferences for follow-up changed between the 
potential low, moderate and intensive regimes were extremely low: hypothetical local recurrence 
risks under 1% were associated with a preference for low intensity follow-up regimes, but 
incremental increases in recurrence risk prompted preferences for higher intensity strategies. 
Indeed, once the hypothetical risk of recurrence rose above 5%, the majority of patients stated 
that an intensive follow-up regime would be most acceptable.  
 
Whilst it is encouraging that patient preferences for sarcoma follow-up do not appear to differ 
significantly from the follow-up regime typically offered by most treatment and surveillance 
centres, it is likely that the broad agreement between patient preference and the current routine 
follow-up regime is at least partly due to ‘the lure of the familiar’. Thus, many patients prioritise 
aspects of follow-up scenarios that match their own current treatment most closely. This 
research was carried out in one centre only, and a larger scale survey may also have shown 
geographical differences in patient preferences. Nevertheless, our research highlights the need 
for a randomised study to determine the optimum strategy for follow-up of sarcoma patients with 
regard to the economic cost, psychological and functional impacts on the patient, the 
effectiveness of different types of imaging, and to establish whether more intensive follow-up 
regimes facilitate earlier detection of local recurrence or metastatic disease than less intensive 
regimes.   
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FIGURE LEGENDS 
 
Figure 1: Best-worst scaling attributes, levels and an example scenario 
 
Figure 2: Participants choosing different follow-up schedules by risk of recurrence  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
Table 1: Participant clinical and sociodemographic characteristics 
Variables Categories Number (%) 
All participants  132 (100.0) 
Clinical information 
 
Median size of tumour (Inter-
quartile range) 8.0cm (5.0 to 12.0cm) 
Grade of primary tumour High 62 (47.0) 
 Intermediate 38 (28.8) 
 Low 28 (21.2) 
 Missing 4 (3.0) 
Site of primary tumour Head and neck 2 (1.5) 
 Upper extremity 25 (18.9) 
 Trunk 17 (12.9) 
 Lower extremity 82 (62.1) 
 Missing 6 (4.5) 
Histological type Fibromyxosarcoma 16 (12.1) 
 Leiomyosarcoma 16 (12.1) 
 Liposarcoma 24 (18.2) 
 Malignant Peripheral Nerve Sheath Tumour (MPNST) 4 (3.0) 
 Synovial sarcoma 12 (9.1) 
 Others 60 (45.5) 
Sociodemographic information 
 
Sex Female 59 (44.7) 
 Male 73 (55.3) 
Median age at survey 
completion (inter-quartile 
range) 
63 years (47 to 71) 
Median age at diagnosis 
(inter-quartile range) 57 years (43 to 67) 
Employment status Permanently employed 33 (25.0) 
 Part time employed 11 (8.3) 
 Self employed 6 (4.5) 
 Retired 69 (52.3) 
 Unemployed 13 (9.8) 
Education No formal qualification 36 (27.3) 
 GCSE/O-Levels  49 (37.1) 
 A-Level 10 (7.6) 
 University  22 (16.7) 
 Postgraduate qualification 15 (11.4) 
Median time from home to 
ROH ( inter-quartile range) 60 minutes (45 to 90) 
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Table 2: Frequency of level selection as the best or worst aspect of a follow-up scenario 
Attributes and levels 
Times 
selected 
as best 
Times 
selected 
as worst 
Best 
minus 
worst 
Rank 
based 
on 
best 
Rank 
based 
on 
worst 
Rank 
based on 
best 
minus 
worst 
Length of follow-up       
5 years 84 98 -14 6 7 5 
10 years 86 113 -27 5 8 6 
Life long 82 165 -83 7 11 9 
Frequency of follow-up       
Once every 12 months 41 94 -53 9 6 8 
Once every 6 months 44 90 -46 8 5 7 
Once every 3 months 35 122 -87 10 10 11 
Preferred clinical 
investigations       
Clinical examination only 175 49 126 3 4 3 
Clinical examination and x-ray 237 11 226 1= 1 1 
Clinical examination and 
intensive investigations 237 21 216 1 2 2 
Healthcare provider    
 
  
General practitioner 19 251 -232 12 12 12 
Specialist hospital nurse 33 119 -86 11 9 10 
Specialist hospital doctor 97 37 60 4 3 4 
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Table 3: Conditional logistic regression of best-worst pairs for all respondents 
Attributes and levels Co-
efficient 
St. 
Error P value 
95% 
Confidence 
interval 
Length of follow-up     
5 years 1.377 0.173 <0.0001 1.04 - 1.72 
10 years 1.296 0.198 <0.0001 0.91 - 1.68 
Life long 0.945 0.212 <0.0001 0.53 - 1.36 
Frequency of follow-up     
Once every 12 months 1.142 0.130 <0.0001 0.89 - 1.40 
Once every 6 months 1.206 0.152 <0.0001 0.91 - 1.50 
Once every 3 months 0.969 0.159 <0.0001 0.66 - 1.28 
Preferred clinical investigations     
Clinical examination only 1.823 0.167 <0.0001 1.49 - 2.15 
Clinical examination and x-ray 2.503 0.171 <0.0001 2.17 - 2.84 
Clinical examination + intensive investigations 2.443 0.197 <0.0001 2.06 - 2.83 
Healthcare provider   
  
General practitioner - - -  
Specialist hospital nurse 1.016 0.136 <0.0001 0.75 - 1.28 
Specialist hospital doctor 1.890 0.175 <0.0001 1.55 - 2.23 
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Figure 1 
Attributes Levels 
Length of follow-up 
visits 
• 5 years 
• 10 years 
• Lifelong 
Frequency of follow-
up visits 
• Every 12 months 
• Every 6 months 
• Every 3 months 
Preferred 
investigations to 
detect recurrence 
• Clinical examination 
• Clinical examination and x-ray 
• Clinical examination and intensive investigation 
(ultrasound/MRI/CT scan) 
Choice of healthcare 
provider 
• General practitioner 
• Specialist hospital nurse 
• Specialist hospital doctor 
EXAMPLE SCENARIO 
BEST THING  WORST THING 
 Follow-up visits will continue for 5 years  
 Follow-up visits will take place every 3 months  
 
Your follow-up visit will be carried out by a specialist 
hospital nurse  
 
A clinical examination and intensive investigations 
(such as ultrasound, MRI, CT scan) will be 
undertaken during your follow-up visit 
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Figure 2 
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